دورية
Use of over-the-scope clip (OTSC) versus standard therapy for the prevention of rebleeding in large peptic ulcers (size ≥1.5 cm): an open-labelled, multicentre international randomised controlled trial
| العنوان: | Use of over-the-scope clip (OTSC) versus standard therapy for the prevention of rebleeding in large peptic ulcers (size ≥1.5 cm): an open-labelled, multicentre international randomised controlled trial |
|---|---|
| المؤلفون: | Chan, Shannon, Pittayanon, Rapat, Wang, Hsiu-Po, Chen, Jiann-Hwa, Teoh, Anthony YB, Kuo, Yu Ting, Tang, Raymond SY, Yip, Hon Chi, Ng, Stephen Ka Kei, Wong, Sunny, Mak, Joyce Wing Yan, Chan, Heyson, Lau, Louis, Lui, Rashid N, Wong, Marc, Rerknimitr, Rungsun, Ng, Enders K, Chiu, Philip Wai Yan |
| المصدر: | Gut; 2023, Vol. 72 Issue: 4 p638-643, 6p |
| مستخلص: | IntroductionOver-the-scope clip (OTSC) has been used recently for primary haemostasis of peptic ulcers. This study aimed to compare the efficacy of OTSC to standard endoscopic therapy in primary treatment of patients with peptic ulcer bleeding that are of size ≥1.5 cm. The target population accounts for only 2.5% of all upper GI bleeders.MethodsThis was a multicentre international randomised controlled trial from July 2017 to October 2020. All patients with Forest IIa or above peptic ulcers of ≥1.5 cm were included. Primary outcome was 30-day clinical rebleeding. Secondary endpoints include 3-day all-cause mortality, transfusion requirement, hospital stay, technical and clinical success, and further interventions. 100 patients are needed to yield a power of 80% to detect a difference of −0.15 at the 0.05 significance level (alpha) using a two-sided Z-test (pooled).Results100 patients were recruited. Success in achieving primary haemostasis was achieved in 46/50 (92%) and 48/50 (96%) in the OTSC and conventional arm, respectively. Among patients who had success in primary haemostasis, 2/46 (4.35%) patients in the OTSC arm and 9/48 (18.75%) patients in the conventional arm developed 30-day rebleeding (p=0.03). However, in an intention-to-treat analysis, there was no difference in rebleeding within 30 days (5/50 (10%) OTSC vs 9/50 (18%) standard, p=0.23) or all-cause mortality (2/50 (4%) OTSC vs 4/50 (8%) standard, p=0.68; OR=2.09, 95% CI 0.37 to 11.95). There was also no difference in transfusion requirement, hospital stay, intensive care unit admission and further interventions.ConclusionThe routine use of OTSC as primary haemostasis in large bleeding peptic ulcers was not associated with a significant decrease in 30-day rebleeding.Trial registration numberNCT03160911. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 00175749 14683288 |
|---|---|
| DOI: | 10.1136/gutjnl-2022-327007 |